Cogstate Ltd · ASX:CGS
Cogstate — Investor Presentation (November 2018)
13 slides from Cogstate's investor presentation, Nov 26, 2018
Slide 1: Investor Presentation
For personal use only Investor Presentation November 2018 © 2018 Cogstate Ltd. All rights reserved.
Slide 2: Investment highlights
Investment highlights For personal use only A world-class cognitive science, technology and services company focused on optimising and monetising the measure of cognition After 10+ years of scientific and commercial validation, Cogstate is now a respected supplier of cognitive science and technolo
Slide 3: Corporate Overview
For personal use only Corporate Overview Strong conviction from long-term shareholders has enabled Cogstate to develop a unique technology platform, extensive validation and expanding supporting services. 44.2% Shareholding of current Board and management Trading information Related party to Non-E
Slide 4: Leaders In Digital Brain Health Assessment
For personal use only Leaders In Digital Brain Health Assessment >70 >100 Languages Indications & Dialects >55 >400 Peer Reviewed Countries Publications 4
Slide 5: Partners to World's Leading Pharma & CROs
For personal use only Partners to World’s Leading Pharma & CROs Cogstate works with 14 of the top 15 pharmaceutical companies ranked by R&D spend, who continue to choose Cogstate for: Expertise in the use of cognitive outcome measures in clinical trials Operational experience and innovative appr
Slide 6: Solutions Provided Via Cogstate eSource Platform
Solutions Provided Via Cogstate eSource Platform For personal use only Central Monitoring Quality Assurance Services Data Management & Reporting Cloud-based Data Management System Cogstate Additional Computerized eCOAs Paper & Pencil Testing (eClinRO, ePRO, Assessments eObsRO) (eCRF) (ePerfO) Softwa
Slide 7: Sales & Revenue Growth
For personal use only Sales & Revenue Growth • 1 clinical trial = 1 sales contract Sales Contracts Executed, by • The value of each contract can range from $100k Financial Year (US$) to $10m+, based upon size and scale of the trial 40,000,000 35,000,000 30,000,000 • Phase 2 and 3 studies run 2-5 yea
Slide 8: Until Now, Profits Invested Back Into The Business
For personal use only Until Now, Profits Invested Back Into The Business • Cogstate has focused on long term return on investment, rather than short term profits • Profits from the Clinical Trials segment were invested in both new technology and launch of Cognigram (use of Cogstate in GP offices) •
Slide 9: Adapting to New Information
For personal use only Adapting to New Information • The impact of the failure of Alzheimer’s trials – Jun-18: study failures resulted in a reduction in contracted future revenue for Cogstate – A treatment for Alzheimer’s disease that would lead to demand for better diagnostic tools could be some tim
Slide 10: Strategy Adjustment Announced Aug-18
For personal use only Strategy Adjustment Announced Aug-18 • Annualised staff costs in excess of $5m removed from the business through restructure implemented from April 2018 – July 2018 – These costs accounted for $3.46m of costs of sales and operating costs in FY18 • In total, 30 roles removed fro
Slide 11: Financial Analysis (US$)
Financial Analysis (US$) For personal use only Full Year Ended 30-Jun-17 30-Jun-18 Revenue from operations 26,404,953 28,956,884 • Clinical Trials sales contracts $36.1m, up 22% Clinical Trials Revenue 26,187,137 28,080,187 • Revenue $28.96m, up 10% Clinical Trials EBITDA 14,861,048 15,905,193 56.7%
Slide 12: FY19 Guidance
For personal use only FY19 Guidance • Contracted revenue position is consistent with the prior year – Even after taking into account Jun-18 contract cancellations due to failure of two potential Alzheimer’s disease therapies • Sales growth prospects are good, but even at flat sales, profit is projec
Slide 13: For personal use only
For personal use only